Back to Search
Start Over
3-Hydroxy-3-methylglutaryl-coenzyme A reductase modulator: toward age- and sex-personalized medicine.
- Source :
-
Expert opinion on therapeutic patents [Expert Opin Ther Pat] 2015; Vol. 25 (10), pp. 1079-83. Date of Electronic Publication: 2015 Jul 01. - Publication Year :
- 2015
-
Abstract
- Cholesterol homeostasis maintenance is regulated by a cellular feedback system that senses cholesterol amount in cellular membranes. 3-hydroxy 3-methylglutaryl coenzyme A reductase (HMGR) plays a pivotal role in cholesterol metabolism as it is the key rate-limiting enzyme of its biosynthetic pathway; its inhibition provokes a feedback response capable of reducing plasma cholesterol content. HMGR inhibition is a keystone in the treatment and prevention of cardiovascular disease and, therefore, statins (HMGR inhibitors) are widely prescribed even though they may sometimes induce side effects. These drugs are prescribed indifferently to both man and women even if there are several well-known differences in cholesterol metabolism depending on the gender and the age. Thus, gender-related differences in cholesterol metabolism should be taken into account to identify new targets for customized pharmacological treatments for hypercholesterolemia.
- Subjects :
- Age Factors
Drug Design
Female
Humans
Hypercholesterolemia drug therapy
Male
Patents as Topic
Precision Medicine
Sex Factors
Anticholesteremic Agents pharmacology
Cholesterol metabolism
Hydroxymethylglutaryl CoA Reductases metabolism
Hydroxymethylglutaryl-CoA Reductase Inhibitors pharmacology
Subjects
Details
- Language :
- English
- ISSN :
- 1744-7674
- Volume :
- 25
- Issue :
- 10
- Database :
- MEDLINE
- Journal :
- Expert opinion on therapeutic patents
- Publication Type :
- Academic Journal
- Accession number :
- 26135220
- Full Text :
- https://doi.org/10.1517/13543776.2015.1061996